Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Biologics and Dutch biotechnology company Crucell have signed a non-exclusive PER.C6 technology research licensing agreement with Brazil-based Recepta Biopharma. The financial details have not been disclosed.
Subscribe to our email newsletter
This agreement allows Recepta Biopharma to use the PER.C6 technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research.
Crucell’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.